GlassScriptPhysician profile
Brian H Margolis
NPI 1336156892
$13,363.48
in general payments reported to CMS, 2019-2025
43 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $1,516 · 2021: $2,343 · 2022: $1,978 · 2023: $1,796 · 2024: $2,137 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,115 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,115.47 |
| Education | $300.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,164.79 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,906.25 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,429.91 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $948.82 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $812.39 | 2019-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $721.85 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $548.52 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $430.03 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $319.21 | 2019-2024 | |
| Grifols USA, LLC | $317.71 | 2019-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $309.69 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $288.48 | 2019-2025 | Zerbaxa |
| La Jolla Pharmaceutical Company | $265.53 | 2021-2022 | |
| Axsome Therapeutics, INC. | $263.06 | 2023-2025 | Sunosi |
| Somnomed INC. | $259.30 | 2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $199.57 | 2019-2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $188.74 | 2023-2025 | Aralast, Glassia |
| Amgen INC. | $181.12 | 2021-2025 | Tezspire |
| Electromed, INC. | $172.93 | 2021-2025 | Smartvest |
| Mallinckrodt Enterprises LLC | $150.76 | 2019 | |
| Gilead Sciences, INC. | $124.77 | 2019 | |
| Baxter Healthcare | $116.81 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Tetraphase Pharmaceuticals, INC. | $116.62 | 2020 | |
| Inspire Medical Systems, INC. | $112.48 | 2023-2025 | Inspire |
| Verona Pharma, INC. | $109.42 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $93.11 | 2024-2025 | Zemaira |
| Advanced Respiratory, INC | $93.03 | 2019-2021 | |
| Pfizer INC. | $83.50 | 2020-2025 | |
| Salvin Dental Specialties, INC. | $75.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2022 | |
| Genentech USA, INC. | $63.49 | 2019 | |
| Insmed, INC. | $56.25 | 2021-2025 | Arikayce |
| Mallinckrodt Hospital Products INC. | $56.22 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $56.02 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $47.10 | 2023-2024 | Purified Cortrophin Gel |
| Resmed Corp | $44.96 | 2023-2024 | |
| Viatris Specialty LLC | $40.11 | 2025 | Yupelri |
| Circassia INC. | $28.85 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $23.53 | 2023 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $19.39 | 2019 | |
| Boston Scientific Corporation | $17.89 | 2021 | |
| Phadia US INC. | $17.06 | 2023 | Immunocap |
| Horizon Therapeutics Plc | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.